|
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Amplification of broad regions of 8q is one of the most frequent genetic alterations in hepatocellular carcinoma (HCC), suggesting the existence of oncogenes in addition to MYC at 8q24.21.
|
22262416 |
2012 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Conclusion: Our findings suggest that Bclaf1 affects HCC progression by manipulating c-MYC mRNA stability and that the Hsp90α/Bclaf1/c-Myc axis might be a potential target for therapeutic intervention in HCC.
|
30015413 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, we investigated the expression and role of FAM83H in 163 human HCCs and further investigated the relationship between FAM83H and oncogene MYC.
|
28607447 |
2017 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of the proto-oncogene c-myc is a common phenomenon in hepatocellular carcinoma (HCC).
|
11148566 |
2001 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
|
30788663 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Cell cycle deregulation in liver lesions of rats with and without genetic predisposition to hepatocarcinogenesis.
|
12029619 |
2002 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
TXNDC9 promotes hepatocellular carcinoma progression by positive regulation of MYC-mediated transcriptional network.
|
30382079 |
2018 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
A combined immunohistochemical and tissue microarray analysis of 81 human HCC tissues revealed that CYLD expression is negatively correlated with expression of proliferation markers Ki-67 and c-MYC.
|
24104553 |
2014 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, we report that a messenger RNA (mRNA) lipid nanoparticle delivering IL-12 (IL-12-LNP) slows down the progression of MYC oncogene-driven HCC.
|
30458889 |
2018 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Activation of the phosphoinositide 3-kinase-AKT, Yes-associated protein (YAP), and MYC pathways is involved in human liver cancers, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC).
|
28964793 |
2017 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Both MYC and transforming growth factor alpha (TGFalpha) are commonly over-expressed in hepatocellular carcinomas, and transgenic mice expressing these genes rapidly develop tumors via the suppression of MYC-induced apoptosis by the growth factor.
|
17698969 |
2007 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The expression of CIP2A and c-MYC was examined by immunohistochemistry in 136 HCC specimens.
|
22847158 |
2012 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In vivo, using liver-specific inducible MYC transgenic mice fed MCD diet, blocking CPT with the pharmacological inhibitor perhexiline decreased apoptosis of intrahepatic CD4<sup>+</sup> T cells and inhibited HCC tumor formation.
|
29795111 |
2018 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The inhibition of HMG-CoA reductase may be a useful target for the treatment of MYC-associated HCC as well as other tumors.
|
21262914 |
2011 |
|
Liver carcinoma
|
0.600 |
Therapeutic
|
disease |
RGD |
Antioxidant N-acetyl-L-cysteine (NAC) supplementation reduces reactive oxygen species (ROS)-mediated hepatocellular tumor promotion of indole-3-carbinol (I3C) in rats.
|
22129741 |
2011 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
TP53, MYC) with epigenomic or genomic alternations driving poor prognoses of HCC patients.
|
27006471 |
2016 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our data also provide a novel mechanistic understanding of GNMT regulation through MYC in the pathogenesis of HCC.
|
30760754 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Compared with results in untreated animals with MYC-induced hepatocellular carcinoma, administration of the GLS-specific inhibitor bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) prolonged survival without any apparent toxicities.
|
25915584 |
2015 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Real-time reverse-transcription polymerase chain reaction (RT-PCR) and northern blot analysis demonstrated reduced expression of the primary, precursor, and mature miR-122 in c-MYC-induced HCCs compared to the benign livers, indicating transcriptional suppression of miR-122 upon MYC overexpression.
|
24038073 |
2014 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Some antigen-expressing <i>MYC;Trp53</i><sup>-/-</sup> HCCs escaped the immune system by upregulating the β-catenin (CTNNB1) pathway.
|
31186238 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Depletion of ARK5 prolongs survival in MYC-driven mouse models of hepatocellular carcinoma, demonstrating that targeting cellular energy homeostasis is a valid therapeutic strategy to eliminate tumour cells that express deregulated MYC.
|
22460906 |
2012 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
For a 10-megabase chromosome region on 8q24, we observed etiology-dependent copy number gains and MYC overexpression in viral and alcohol-related HCCs, resulting in up-regulation of MYC target genes.
|
18161050 |
2008 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Myc target gene, long intergenic noncoding RNA, Linc00176 in hepatocellular carcinoma regulates cell cycle and cell survival by titrating tumor suppressor microRNAs.
|
28869604 |
2018 |
|
Liver carcinoma
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
Combination of hepatocyte specific delivery and transformation dependent expression of shRNA inducing transcriptional gene silencing of c-Myc promoter in hepatocellular carcinoma cells.
|
25108398 |
2014 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Compelling evidence demonstrates that DLC1, a potent TSG on 8p, and MYC oncogene on 8q play a critical role in the pathogenesis of human HCC.
|
22580498 |
2012 |